SL Science notifies availability of press release on WCP 2026 glioblastoma research update
SLBT•Press release posted on WCP 2026 glioblastoma data
SL Science posted a press release on its WCP 2026 presentation of preclinical glioblastoma data for its gamma delta T-cell therapy platform.
- Study results showed complete tumor elimination by day 26 at the highest dose tested, with dose-dependent efficacy on repeat dosing.
- Safety screens reported no major adverse effects in the preclinical models.
